Search the Newsreel

bioAffinity Technologies closes $4M private placement By Investing.com

bioAffinity Technologies (NASDAQ:BIAF) has successfully completed a private placement, raising approximately $4.0 million. The placement involved pre-funded warrants to purchase over 8.4 million shares of common stock, along with accompanying standard warrants. The funds raised will support the company's operations, including the development of …

bioAffinity Technologies closes $4 million private placement of pre-funded warrants priced at $0.47

bioAffinity Technologies has successfully closed a private placement, raising approximately $4 million in gross proceeds from pre-funded warrants. The placement involved 8,462,027 common shares, with each pre-funded warrant priced at $0.47 and accompanied by two additional warrants. WallachBeth Capital acted as the sole placement …

bioAffinity Technologies prices $4M private placement offering

bioAffinity Technologies (NASDAQ:BIAF) has announced a private placement offering aiming to raise approximately $4.0 million. The company will sell 8,462,027 shares of common stock or pre-funded warrants, alongside warrants to purchase up to 16,924,054 shares, to an institutional investor. The offering is expected to …

Affin Bank H1 Profit Falls 1.7%; Impairment Charges Triple

Fund Update: 120,552 $IJR Shares Added to FIRST FINANCIAL BANKSHARES INC Portfolio

This article reports that 120,552 shares of iShares Core S&P Small-Cap (IJR) were added to the FIRST FINANCIAL BANKSHARES INC (FFIN) portfolio. This information indicates a notable increase in the fund's holdings of this particular ETF.

First Financial Bankshares, Inc. (NASDAQ:FFIN) Given Average Rating of "Moderate Buy" by Brokerages

First Financial Bankshares, Inc. (NASDAQ:FFIN) has received an average "Moderate Buy" rating from brokerages, with an average 12-month price target of $36.75. The company's recent earnings matched expectations, reporting $0.50 EPS and $172.76 million in revenue, and analysts project $2.04 EPS for the current …

First Financial Bankshares (FFIN) Expanded Its Buyback Plan, Is The Upside Already Priced In?

First Financial Bankshares, Inc (FFIN) Stock Forecasts

Argus has raised its target price for First Financial Bankshares Inc (FFIN) to $36.00, noting that the company operates as a financial and bank holding company primarily in Texas. The report provides a summary of FFIN's operations and encourages users to upgrade to Yahoo …

Fund Update: New $27.6M $FSCC stock position opened by FIRST FINANCIAL BANKSHARES INC

FIRST FINANCIAL BANKSHARES INC has opened a new $27.6 million position in its own stock, FSCC, according to a recent SEC 13F filing for the Q2 2026 report period. This move highlights significant institutional investor activity in FSCC, with 34 investors increasing their positions …

First Financial Bankshares (FFIN) reports $5.34B in Form 13F equity holdings

First Financial Bankshares Inc. (FFIN) has filed its quarterly Form 13F-HR, disclosing U.S. equity holdings totaling $5.34 billion across 210 individual positions. The report includes holdings managed by First Financial Trust & Asset Management Company. This filing provides transparency into the institutional investor's portfolio …

bioAffinity Technologies to Add Mexican Patent to its CyPath Lung Technology IP

bioAffinity Technologies Inc. has received notification of patent allowance in Mexico for its CyPath Lung technology, further strengthening its global intellectual property portfolio. This patent protects the use of flow cytometry and specific labeling methods for detecting lung cancer cells in sputum, expanding on …

Renaissance Technologies LLC Sells 55,000 Shares of First Financial Bankshares, Inc. $FFIN

Renaissance Technologies LLC reduced its stake in First Financial Bankshares (FFIN) by 37.2% in the first quarter, selling 55,000 shares but still retaining 92,808 shares worth approximately $2.7 million. Institutional investors now own 69.78% of the company, with other large investors increasing their positions. …

First Trust Advisors LP Sells 62,634 Shares of First Financial Bankshares, Inc. $FFIN

First Trust Advisors LP reduced its stake in First Financial Bankshares (NASDAQ:FFIN) by 53.9% in the first quarter, selling 62,634 shares and retaining 53,616 shares valued at $1.58 million. Despite this, institutional investors still collectively own 69.78% of the company. First Financial Bankshares reported …

Affinity Bancshares Inc (AFBI) Earnings Forecast: Future EPS & Revenue Growth Estimates

BGSF Inc (BGSF) Earnings Forecast: Future EPS & Revenue Growth Estimates

BGSF Inc (BGSF) currently lacks an earnings forecast score, with the Professional & Commercial Services industry averaging 7.68. Analysts have set a unanimous price target of $10.50 for BGSF, indicating a potential upside of 169.23%. The company's expected revenue for the next quarter is …

First Financial Bankshares, Inc. Revenue Breakdown – NASDAQ:FFIN

First Financial Bankshares, Inc. (FFIN) generated $631.60 million USD in revenue last year, primarily from its Community Banking segment. This represents an increase from $550.73 million USD in the previous year. The entire revenue contribution came from operations within the United States.

Form 8K bioAffinity Technologies Inc For: 7 August By Investing.com

The article reports that bioAffinity Technologies Inc. filed a Form 8K on August 7th. It briefly mentions the company's stock symbol BIAF and includes general financial market data such as indices, commodities, and shares. The content is primarily a placeholder or boilerplate for financial …

Sei Investments Co. Boosts Holdings in First Financial Bankshares, Inc. $FFIN

Sei Investments Co. significantly increased its stake in First Financial Bankshares (NASDAQ:FFIN) by 60% in the first quarter, now owning 112,380 shares valued at $3.3 million. This move is part of a broader trend of institutional investment, with collective ownership reaching 69.78%. Analysts maintain …

bioAffinity Technologies, Inc. Q2 2026: Revenue $1.51M, EPS $(0.64) — 10-Q Summary

bioAffinity Technologies, Inc. (BIAF) reported its Q2 2026 financial results, with revenue increasing by 19% year-over-year to $1.51M. The company narrowed its net loss to $3.37M, and diluted loss per share improved to $(0.64). Key business highlights include significant growth in CyPath® Lung revenue …

BioAffinity Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

BioAffinity Technologies, Inc. has released its earnings results for the second quarter and six months ending June 30, 2026. For the second quarter, the company saw an increase in sales to USD 1.51 million compared to USD 1.27 million a year ago, while reducing …

Press Release: BioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath(R) Lung

BioAffinity Technologies announced its financial results for the second quarter of 2026, highlighting strong commercial growth for its CyPath® Lung diagnostic. The company reported a significant increase in test volumes and revenue compared to the previous year, driven by expanding insurance coverage and successful …

Earnings call transcript: BGSF misses Q2 2026 revenue forecast as cost cuts help

BGSF reported mixed Q2 2026 results, missing revenue forecasts but showing improved profitability due to significant cost reductions after becoming a standalone company. While revenue declined by 5.1% year-over-year, adjusted EBITDA losses narrowed considerably, indicating the effectiveness of its restructuring efforts. The company is …

BGSF, Inc. Announces Special Cash Dividend of $2.00 Per Share

BGSF, Inc. has announced a special cash dividend of $2.00 per share, payable on September 30, 2025, to shareholders of record as of September 23, 2025. This decision by the Board of Directors is an initial step in allocating capital from the sale of …

BGSF Inc (BGSF) (Q2 2026) Earnings Call Highlights: Strategic Cost Cuts Drive Margin ...

BGSF Inc (BGSF) reported its Q2 2026 earnings, highlighting significant reductions in SG&A expenses by 29% year-over-year, leading to an improved adjusted EBITDA loss despite a 5.1% decline in revenue. The company is focusing on operational efficiency, AI-driven candidate matching, and the growth of …

bioAffinity Technologies earnings beat by $1.46, revenue fell short of estimates

bioAffinity Technologies (NASDAQ: BIAF) reported a second-quarter EPS of $-0.640, significantly beating the analyst estimate of $-2.100 by $1.46. However, the company's revenue for the quarter was $1.5M, falling short of the consensus estimate of $1.7M. The stock has experienced a significant decline over …

BGSF, Inc. (NYSE: BGSF) director receives new option and stock awards

BGSF, Inc. director Douglas Hailey reported on August 4, 2026, receiving equity compensation awards including 5,000 stock options at an exercise price of $5.58 per share, exercisable in tranches from 2026 to 2030 and expiring in 2036. He also acquired 3,360 shares of common …

Affinity Bancshares (NASDAQ: AFBI) EVP equity cashed out at $23 per share

Affinity Bancshares' EVP of Lending, Elizabeth Galazka, reported dispositions of common stock and stock options on August 1, 2026, due to a merger. All directly and indirectly held common shares, including those from her spouse, IRAs, and ESOP, were converted into a right to …

Affinity Bancshares (AFBI) COO equity gets $23.00 per share in merger

Affinity Bancshares' Chief Operations Officer, Robert Vickers, disposed of his equity holdings in AFBI as part of a merger agreement. His common shares were converted into cash at $23.00 per share, and stock options were converted into cash equal to $23.00 minus their exercise …

bioAffinity Technologies reports Q2 2026 revenue $1.51M, net loss $3.37M, cash $2.43M

bioAffinity Technologies reported its Q2 2026 financial results, showing revenue of $1.51 million, an increase from $1.27 million in Q2 2025, and a net loss of $3.37 million, an improvement from $4.06 million in Q2 2025. The company's cash and cash equivalents decreased to …

BIAF: Q2 2026 saw 216% CyPath Lung test growth and 19% revenue increase, with improved net loss

BioAffinity Technologies (BIAF) reported significant growth in Q2 2026, with CyPath Lung test volume increasing by 216% and revenue by 19%. This growth was attributed to accelerated physician adoption and expanded clinical trials. Despite increased operating expenses due to commercialization efforts, the company improved …

BGSF: Revenue fell 5.1% year-over-year as cost controls improved margins and PropTech ramped up

BGSF (BGSF) reported a 5.1% year-over-year revenue decline in Q2 2026, reaching $22.3 million. Despite this, the company saw improved adjusted EBITDA loss and significant reductions in selling, general, and administrative expenses due to cost controls. BGSF is focusing on operational streamlining and expanding …

Affinity Bancshares Inc (AFBI) Stock News Today

First Financial Bank announces Abilene leadership changes By Investing.com

First Financial Bank has announced significant leadership changes in its Abilene Region, including the retirement of Marelyn Shedd after 35 years of service. Marshall Morris will take over as Chairman, President, and CEO of the Abilene Region, with additional promotions for Evan Harris and …